Haematopoietic Stem Cell Transplantation Increases Survival in Systemic Sclerosis Patients PDF Print E-mail
Thursday, 07 June 2012 21:48
Initial results from an international, investigator-initiated, open label phase III trial were presented at EULAR 2012, the Annual Congress of the European League Against Rheumatism. Data indicate that haematopoietic stem cell transplantation (HSCT) results in better long term survival than conventional treatment for patients with poor prognosis early diffuse cutaneous systemic sclerosis.

The ASTIS (Autologous Stem Cell Transplantation International Scleroderma) trial enrolled more than 150 patients between 2001 and 2009, and randomised patients to the HSCT arm or to intravenous pulse cyclophosphamide treatment. As of May 1, 2012, significantly more deaths have occurred in the conventional treatment group. Half of the deaths in the HSCT group occurred early and were deemed treatment-related according to an independent data monitoring committee. In the conventional treatment group in contrast, none of the deaths were deemed to be treatment-related; but more deaths occurred later and most were related to progressive disease.

"Systemic sclerosis is a debilitating disease that can lead to heart, lung or kidney failure and premature death, especially in patients who have the diffuse cutaneous form of the condition, where skin thickening is more generalised and involvement of vital organs more common. The ASTIS study shows that such patients may benefit from early intensive immunosuppressive treatment," said Professor Jaap van Laar from Newcastle University, Professor Dominique Farge, Assistance Publique Hopitaux de Paris (Sponsor in France, Paris 7 University) and Professor Alan Tyndall from Basel University, on behalf of their colleagues from the EBMT EULAR Scleroderma Study Group. "These initial results are very encouraging and will help identify patients who benefit from stem cell transplantation."

The ASTIS trial was a unique collaborative project of 27 multidisciplinary teams from 10 countries conducted under the auspices of two leading organisations in the respective fields, the European Group for Blood and Marrow Transplantation (EBMT; www.ebmt.org) and the European League Against Rheumatism (EULAR; www.eular.org). The primary endpoint of the trial was event-free survival, defined as survival until death or development of major organ failure.

Systemic sclerosis is a rare but severe autoimmune systemic connective tissue disease. Increased fibroblast activity results in abnormal growth of connective tissue which causes vascular damage and fibrosis of the skin, gastrointestinal (GI) tract and other internal organs. Characteristics of systemic sclerosis include vasomotor disturbances; fibrosis; subsequent atrophy of the skin, subcutaneous tissue, muscles, and internal organs and immunologic disturbances. Systemic sclerosis is estimated to occur in 2.3-10 people per one million. Diffuse cutaneous systemic sclerosis cases make up 30% of all systemic sclerosis cases and involve the upper arms, thighs and trunk. Lung fibrosis and pulmonary hypertension are important causes of mortality in these patients and there is no curative treatment available so far.

Source: Eurekalert (2012), "Haematopoietic stem cell transplantation increases survival in systemic sclerosis patients"; original press release can be viewed here.

 
More articles :

» New Classification Criteria Developed For Scleroderma

The 2013 Classification Criteria for Systemic Sclerosis have been developed and validated by the and and should allow patients to be identified and treated earlier, according to the professional bodies.Published in Arthritis and Rheumatism, the...

» Digital Ulcers Linked to More Severe Systemic Sclerosis

Digital ulcers are associated with more severe systemic sclerosis (SSc) disease, including skin and lung involvement, but not with pulmonary arterial hypertension (PAH) or scleroderma renal crisis (SRC), according to research published in the...

» PDE-5 Inhibitors in Scleroderma Raynaud Phenomenon and Digital Ulcers

Systemic sclerosis- (SSc-) related vasculopathy, as manifested by Raynaud’s Phenomenon (RP) and digital ulcers (DUs), is associated with significant impairment of the quality of life and morbidity. The current vasoactive approach for SSc-RP,...

» Neutrophil Elastase Regulator Needed in Systemic Sclerosis

, which promotes and fibrosis, is suspected of playing a role in (SSc). Theresa C. Barnes, MD, from University of Liverpool, Aintree University Hospital, United Kingdom, and colleagues  of Rheumatology that the problem may not be too...

» FDA Approves New Lupus Drug

The FDA has approved (Benlysta) for reducing disease activity in (SLE), making it the first new lupus drug in more than 50 years. Belimumab is a monoclonal antibody targeting the B-lymphocyte stimulator protein, called BLyS. It was co-developed by...

» Cancer Risk Among Patients With Systemic Sclerosis: A Nationwide Population Study In Taiwan

C-F Kuo, S-F Luo, K-H Yu, I-J Chou, W-Y Tseng, H-C Chang, Y-F Fang, M-J Chiou, L-C SeePosted online on December 11, 2011Objectives: Systemic sclerosis (SSc) has been associated with high cancer risk. We compared the cancer risk among SSc patients...